The identification of new genetic lesions in chronic lymphocytic leukemia (CLL) prompts a comprehensive and dynamic prognostic algorithm including gene mutations, chromosomal abnormalities, and their changes during clonal evolution. By integrating mutational and cytogenetic analysis in 1274 CLL samples, and by using both a training-validation and a time-dependent design, four CLL subgroups were hierarchically classified: i) high-risk, harboring TP53 and/or BIRC3 abnormalities (10-year survival:29%); ii) intermediate-risk, harboring NOTCH1 and/or SF3B1 mutations and/or del11q22-q23 (10-year survival:37%); iii) low-risk, harboring +12 or a normal genetics (10-year survival:57%); iv) very low-risk, harboring del13q14 only, whose 10-year survival (69.3%) did not significantly differ from a matched general population. This integrated mutational and cytogenetic model independently predicted survival, improved CLL prognostication accuracy compared to FISH karyotype (p<0.0001), and was externally validated in an independent CLL cohort. Clonal evolution from lower to higher risk implicated the emergence of NOTCH1, SF3B1 and BIRC3 abnormalities in addition to TP53 and 11q22-q23 lesions. By taking into account clonal evolution through time-dependent analysis, the genetic model maintained its prognostic relevance at any time from diagnosis. These findings may have relevant implications for the design of clinical trials aimed at assessing the use of mutational profiling to inform therapeutic decisions.
INTRODUCTION
The course of chronic lymphocytic leukemia (CLL) ranges from very indolent with a nearly normal life expectancy, to rapidly progressive leading to early death. 1, 2 To better understand the genetic basis of CLL heterogeneity and improve patients' prognostication, all recurrent and clinically relevant molecular lesions should be combined into a comprehensive prognostic model.
Chromosomal aberrations and TP53 mutations are of key importance for predicting CLL outcome. 3, 4 Recently, next generation sequencing has disclosed a further degree in the molecular complexity of CLL by revealing novel genetic lesions affecting the NOTCH1, SF3B1, MYD88 and BIRC3 genes. [5] [6] [7] [8] [9] Alterations of these genes occur in ~5-10% CLL at diagnosis and, in the case of NOTCH1, SF3B1 and BIRC3, have individually shown significant correlations with survival in consecutive series from independent institutions. [5] [6] [7] [8] [9] [10] [11] These findings prompt the integration of the newly discovered genetic lesions into a model based on both chromosomal abnormalities and gene mutations.
Available genetic prognostic models in CLL are based on the evaluation of risk factors detected at a specific time point. [3] [4] The appearance of additional genetic lesions during CLL course may dynamically modify patients' survival, as suggested by the association between clonal evolution and poor prognosis, treatment resistance and transformation. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] On these bases, a dynamic prognostic model based on a time-dependent analysis of CLL genetic lesions may prove useful for a better understanding of disease outcome.
Here we report an integrated mutational and cytogenetic model for CLL survival prediction that maintains its prognostic relevance in a time-dependent fashion.
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From
METHODS

Patients
Time-fixed analysis at diagnosis was based on a training series of 637 newly diagnosed and previously untreated CLL patients of whom 583 (91.5%) were provided with regular follow-up.
Among CLL from the training series that required treatment, 122/266 (45.8%) cases received rituximab-based regimens (i.e. fludarabine-cyclophosphamide-rituximab, fludarabine-rituximab or pentostatin-cyclophosphamide-rituximab), 64/266 (24.0%) fludarabine-based regimens (i.e. fludarabine or fludarabine-cyclophosphamide), and 80/266 (30.1%) alkylator-based regimens (i.e. chlorambucil). To externally validate the results of the time-fixed analysis, an independent cohort of 370 newly diagnosed and previously untreated CLL was also investigated. Time-dependent analysis and analysis of clonal evolution were based on a mono-institutional cohort of 257 CLL out of the training series that was provided with sequential tumor samples (n=469) and clinical information prospectively collected at clinically relevant time points (i.e. diagnosis, progression, last follow-up).
Further details of the study populations are available in table S1 and in the Supplementary Methods. CLL diagnosis was according to 2008 IWCLL-NCI criteria and confirmed by a flow cytometry score >3 in all cases.
2 Monoclonal B-cell lymphocytosis (MBL) were excluded. The study was approved by the institutional ethical committee (Protocol Code 59/CE; Study Number CE 8/11).
Patients provided informed consent in accordance with local IRB requirements and Declaration of Helsinki.
Samples
Overall, 1274 CLL samples were subjected to mutational and FISH analysis. CLL samples were extracted from fresh or frozen peripheral blood mononuclear cells (PBMC) isolated by FicollPaque gradient centrifugation. In all cases, the fraction of tumor cells corresponded to >70% as assessed by flow cytometry. Matched normal DNA from the same patient was obtained from saliva
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From or from purified granulocytes and confirmed to be tumor-free by PCR of tumor-specific IGHV-D-J rearrangements. High-molecular-weight (HMW) genomic DNA was extracted from tumor and normal samples according to standard procedures. DNA was quantified by the NanoDrop 2000C spectrophotometer (Thermo Scientific).
Molecular studies
The mutation hotspots of TP53 (exons 4-9, including splicing sites; RefSeq NM_000546.5), NOTCH1 (exon 34; RefSeq NM_017617.2), SF3B1 (exons 14, 15, 16, 18, including splice sites; RefSeq NM_012433.2), MYD88 (exons 3, 5, including splicing sites; RefSeq NM_002468.4), and BIRC3 (exons 6-9, including splicing sites; RefSeq NM_001165.4) genes were analyzed by PCR amplification and DNA direct sequencing of high molecular weight genomic DNA. 8, 10, 11 The mutant allele frequency was estimated by next generation sequencing. 5 Amplicons known to harbor TP53, NOTCH1, SF3B1, MYD88, or BIRC3 mutations by Sanger sequencing were reamplified from genomic DNA by oligonucleotides containing the gene-specific sequences, along with 10-bp MID tag for multiplexing and amplicon library A and B sequencing adapters. The obtained amplicon library was subjected to deep sequencing on the Genome Sequencer Junior instrument (454 Life Sciences). 5 In order to obtain ~700-fold coverage per amplicon, no more than 100 amplicons/run were analyzed. The obtained sequencing reads were mapped to reference sequences and analyzed by the Amplicon Variant Analyzer software (Roche) to establish the mutant allele frequency.
Probes used for FISH analysis were: i) LSID13S319, CEP12, LSIp53, LSIATM (Abbott); ii) RP11-177O8 (BIRC3) BAC clone. 11 Further details of the molecular studies are available in the Supplementary Appendix.
Statistical analysis
Overall survival (OS) was the primary endpoint and was measured from date of initial presentation to date of death from any cause (event) or last follow-up (censoring). Treatment free 23, 24 Recursive partitioning was applied to divide patients in genetic subgroups with different outcome. 25 The stability of the recursive decision tree was validated by the random survival forest method. 26 An amalgamation algorithm was used to merge terminal nodes showing homogenous survival. 25 Relative survival, defined as the ratio between the actuarial survival observed in the CLL cohort and the expected survival of the general Italian population matched to CLL patients by sex, age and calendar year of diagnosis, was calculated using the Ederer II method. 
RESULTS
Mutational complementation groups and independent prognostic value of genetic lesions in newly diagnosed CLL As a preliminary step toward the construction of an integrated mutational and cytogenetic model, we assessed the prevalence and independent prognostic value of the candidate genetic lesions in the training series of 637 CLL (Tables S1-S2-S3). Del13q14 and +12 distributed in a mutually exclusive fashion (p<0.0001) (Fig. S1, Fig. S2 ). With the sole exception of the expected association between NOTCH1 mutations and +12 CLL (p=0.0014), 27 ,28 the prevalence of other genetic lesions did not differ among molecular subgroups (Fig. S1, Fig S2) . Consistent with a dual hit mechanism of inactivation, mutations of both TP53 and BIRC3 frequently co-occurred with deletion of the corresponding locus (p<0.0001 and p=0.0065, respectively) ( Fig. S1, Fig S2) .
Analysis of FISH abnormalities reproduced the previously described prognostic groups in this study cohort (Table S3 , Fig. S3 ). 3 Patients harboring del17p13 and patients harboring TP53 mutations in the absence of del17p13 showed an identical outcome in the study cohort and therefore were combined for the analysis of outcome. 13 Among new CLL lesions, survival analysis confirmed the independent prognostic value of NOTCH1, SF3B1 and BIRC3 abnormalities (Table S3) . MYD88 mutations had no prognostic effect (p=0.1728), although the study was adequately powered (90%)
for detecting the impact of these low frequency (~4%) mutations on survival.
This preliminary assessment provided the rationale for including alterations of NOTCH1, SF3B1, and BIRC3, in addition to standard FISH lesions and TP53 mutations, in the subsequent development of an integrated mutational and cytogenetic model.
Integrated mutational and cytogenetic model for CLL prognostication
The hierarchical order of relevance of the genetic lesions in predicting CLL survival was established by recursive partitioning analysis of the training series (Fig. 1) . 25, 26 TP53 disruption was
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From the most predictive genetic variable in the survival tree, followed by BIRC3 disruption, mutations of SF3B1 and NOTCH1, and del11q22-q23 (Fig. 1) . In CLL lacking all the aforementioned abnormalities, +12 and del13q14 further stratified patients' outcome. Measure of the variable importance validated the hierarchical order of relevance of the genetic lesions established by the recursive partitioning analysis and confirmed the stability of the decision tree (Table S4) . 26 Based on the application of the amalgamation algorithm to the terminal nodes, 25 cases harboring TP53 abnormalities and cases harboring BIRC3 abnormalities were grouped into a single category, as well as cases harboring NOTCH1 mutations, SF3B1 mutations or del11q22-q23. This approach allowed to establish an integrated mutational and cytogenetic model for classifying newly diagnosed CLL patients according to risk of death.
Four CLL subgroups were hierarchically classified ( Fig. 2) . The high-risk category included patients harboring TP53 disruption and/or BIRC3 disruption independent of co-occurring lesions (5-year OS: 50.9%; 10-year OS: 29.1%) ( Fig. 2A) . When the demographic effects of age, sex and year of diagnosis were compensated, the 10-year life expectancy of high-risk patients was only 37.7% of that expected in the matched general population (p<0.0001) (Fig. 3B ).
The intermediate-risk category included patients harboring NOTCH1 and/or SF3B1 mutations and/or del11q22-q23 in the absence of TP53 and BIRC3 abnormalities (5-year OS:
65.9%; 10-year OS 37.1%) ( Fig. 2A) . The 10-year life expectancy of intermediate-risk patients was only 48.5% of that expected in the matched general population (p<0.0001) (Fig. 3B ).
The low-risk category (5-year OS: 77.6%; 10-year OS: 57.3%) comprised both patients harboring +12 and patients wild type for all genetic lesions (i.e. normal) ( Fig. 2A) . Though experiencing an indolent behavior, the 10-year life expectancy of low-risk patients was 70.7% of that expected in the matched general population (p<0.0001) (Fig. 3B ).
The very low-risk category included patients harboring del13q14 as the sole genetic lesion (5-year OS: 86.9%; 10-year OS 69.3%) ( Fig. 2A) . Notably, the 10-year life expectancy of very lowrisk patients was only slightly (84.2%) and not significantly (p=0.1455) lower than that expected in
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Differences in outcome among the four subgroups were consistent with: i) differences in prevalence of unfavorable clinical and biological features at presentation (Table S5) ; and ii) differences in disease progression, as indicated by TFS (Fig. 2B ).
Because the higher risk genetic groups contain more patients with advanced stage disease, we also limited the survival analysis to Rai 0-I CLL. Consistent with the results obtained in the whole CLL population, the genetic model stratified four genetic subgroups also in early stage CLL (Fig. S4) .
In order to provide a preliminary signal on the reproducibility of the prognostic model in patients treated with rituximab-containing regimens, we have analyzed the impact of the model on: Overall, these data establish the hierarchical order of relevance of recurrent mutations and cytogenetic lesions in CLL and identify four distinct prognostic subgroups.
The integrated mutational and cytogenetic model is an independent and reproducible predictor of OS in CLL
Multivariate analysis selected the genetic model as an independent risk factor of OS in the training series (p trend =0.0010), along with age (p<0.0001), Rai stage (p trend <0.0001) and unmutated IGHV genes (p=0.0036) ( Table 1) . Internal validation on 1000 bootstrap samples confirmed the stability of the genetic model as a prognostic factor of OS in the training series (Table 1) .
Survival analysis in an independent external validation series of 370 newly diagnosed CLL confirmed: i) the more general reproducibility of the genetic model in predicting OS (Fig. S6) ; ii) its capacity of discriminating patients' outcome (c-index in the validation series 0.662: vs c-index in the training series: 0.642), and iii) its independent prognostic value (p trend =0.0053) when adjusted for other confounding covariates (Table S6 ).
Based on these data, the genetic model represents one of the most important independent prognosticators of CLL survival in both the training and the validation cohorts.
Inclusion of mutations in addition to FISH abnormalities significantly improves the accuracy of CLL prognostication
Overall, ~20% (105/488) of lower risk patients according to the FISH cytogenetic model, 3 including 20.1% (39/194) del13q14 only CLL, were reclassified into higher risk subgroups by the integrated mutational and cytogenetic model because of the co-occurrence of NOTCH1, SF3B1, TP53 mutations or BIRC3 disruption (Table S7) . Consistently, the inclusion of TP53, NOTCH1, and SF3B1 mutations, and of BIRC3 lesions in addition to FISH abnormalities significantly improved the accuracy of survival prediction (c-index: 0.617 vs c-index: 0.642 p<0.0001) (Fig. 3) .
Based on the sole FISH assessment, the life expectancy of del13q14 only CLL was significantly lower (68.1%; p<0.0001) than that expected in the matched general population (Fig.   3A) . Conversely, the genetic model segregated a subgroup of patients with del13q14 only who lacked other genetic alterations and showed an expected survival not significantly different from
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On these grounds, integrating mutations and cytogenetic lesions proves useful to refine the prognosis of CLL and helps identifying a subgroup of patients with an extremely indolent disease.
Assessment of clonal evolution in CLL by integrated mutational and cytogenetic analysis
In order to clarify the evolution of NOTCH1, SF3B1, and BIRC3 lesions, we repeatedly analyzed CLL patients provided with >2 sequential samples (n=202) followed for at least 2 years after presentation (median interval between baseline and last sequential sample: 62.8 months, range 24-150 months). FISH lesions and TP53 mutations were also investigated. Among cases that were informative at presentation, TP53, NOTCH1, SF3B1, MYD88 and BIRC3 mutant allele frequency did not significantly change during disease course (Fig. S7) . Clonal fluctuation, defined as the disappearance of a mutated clone, occurred in only three cases. Notably, in all three cases the baseline mutated clone was substituted by a second clone harboring a new high risk mutation (Table S8, Fig. S8 ).
These data document that, similarly to TP53 abnormalities and del11q22-q23, also NOTCH1, SF3B1 and BIRC3 lesions may emerge during clonal evolution. 
Baseline factors associated with high risk clonal evolution
To investigate the dynamics of acquisition of high risk genetic lesions during follow-up, we evaluated the time to clonal evolution and its modifications according to the disease characteristics at diagnosis after adjusting for death as a competing risk.
At 10 years from diagnosis, 24.5% CLL belonging to the very low-and low-risk genetic subgroups had developed new TP53, NOTCH1, SF3B1, BIRC3 or del11q22-q23 lesions due to clonal evolution, and therefore switched to a higher risk category of the genetic model. Clinical features at presentation predicting the development of new high risk genetic lesions were age >65 years (p=0.0192), high LDH (p=0.0093), and unmutated IGHV genes (p=0.0087) (Fig. 4A-C) .
Consistent with their inferior OS probability, cases belonging to the low-risk subgroup according to the genetic model (i.e. cases harboring +12 or a normal genetics) showed a significantly higher probability of developing poor risk genetic lesions and of switching to intermediate-or high-risk subgroups compared to very low-risk CLL harboring del13q14 only (p=0.0435) (Fig. 4D) . The increased risk of clonal evolution in cases harboring +12 or a normal genotype may be explained by the higher prevalence of unmutated IGHV genes (Table S5 ) and the higher risk of treatment requirement (Fig. 2 ) observed in these cases compared to del13q14 only CLL.
Impact of high risk clonal evolution on CLL survival
In traditional Kaplan-Meier or Cox regression analysis, usually a risk factor measured at baseline is related to mortality thereafter. However, the development of poor risk factors during disease course may substantially modify the patient's outcome, and estimates of prognosis should improve if such time-dependent changes are taken into account. Thus, we investigated whether the assessment of clonal evolution contributes to improve OS prediction by using a time-dependent Cox regression analysis. This analysis included variables considered "fixed" in time (i.e. sex and IGHV mutation status) and time-varying variables (i.e. age, Rai stage and status of the genetic lesions) that For personal use only. on July 15, 2017. by guest www.bloodjournal.org From were repeatedly assessed at clinically relevant time points (i.e. disease progression or last followup).
Time-varying genetic lesions associated with short OS were TP53 disruption (p<0.0001), BIRC3 disruption (p=0.0166), and NOTCH1 mutations (p=0.0247). SF3B1 mutations were of borderline significance (p=0.0766) (Table S10 ). Dynamic changes of the genetic model due to clonal evolution retained a statistically significant impact on OS (p trend =0.0003), independent of modifications affecting other time-varying factors, such as patients' age and disease stage (Table   S11 ). Consistently, the genetic model stratified CLL OS at 1, 2 and 4 years from diagnosis by landmark analysis (Fig. 5) .
These results document the prognostic relevance of developing high-risk genetic lesions during CLL course, and show that the genetic model maintains its prognostic impact at any time from diagnosis.
DISCUSSION
We provide an integrated mutational and cytogenetic model for CLL prognostication that: i) allows to segregate four patient subgroups with distinct risks of death in a fashion that is reproducible and independent from other well established prognosticators; ii) takes into account clonal evolution; and iii) maintains its independent prognostic relevance at any time point from diagnosis.
In terms of discriminating the patients' course, the integrated mutational and cytogenetic model significantly adds to the model based solely on FISH karyotype. 3 Due to the co-occurrence of unfavorable mutations, ~20% of patients belonging to low-risk cytogenetic subgroups are reclassified into one of the two highest risk genetic categories. This refinement allows to segregate a subgroup of CLL harboring del13q14 only that account for a relevant fraction (~25%) of newly diagnosed patients and show an expected survival only slightly, though not significantly, lower than that of the general population. The small residual excess mortality observed in this subgroup may be due to the inclusion in the case mix of patients harboring poor risk genetic lesions that are currently unknown and/or patients with a complex karyotype that is not captured by FISH approaches. 30 The very favorable outcome of del13q14 only CLL may be explained by their slow progression rate (~4% per year), documenting that del13q14 only CLL is a highly stable clinical entity. Notably, the progression rate of del13q14 only CLL is in the order of magnitude of that described in other conditions considered as pre-malignant. 31, 32 Recursive partitioning allowed to define that SF3B1 and NOTCH1 mutations are hierarchically classified after TP53 and BIRC3 lesions. Consistently, patients harboring NOTCH1 or NOTCH1, SF3B1 and BIRC3 lesions, even though absent at presentation, may emerge during disease course, thus expanding the spectrum of genetic events currently associated with high-risk clonal evolution that were so far limited to TP53 abnormalities and del11q22-q23.
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Overall, the probability of developing new high-risk genetic lesions is substantial (~25% at 10-years), and the acquisition of high-risk genetic lesions over time affects survival in a manner that is independent of modifications of other time-varying factors, such as patient age and disease stage.
On these bases, one additional goal of the study was to establish a dynamic model accounting for all prognostically meaningful genetic lesions and their modifications during disease course due to clonal evolution. According to this dynamic approach, the integrated mutational and cytogenetic model retains its prognostic relevance at any time point during the clinical course, and the hazard of death increases any time a CLL patient shifts to a higher risk category of the genetic model. These results point to the relevance of sequentially reassessing the parameters of the genetic model when an updated genetic status is required for redefining the precise prognosis of the patient. The probability of undergoing clonal evolution is not uniform across CLL patients, but varies according to patients' age and baseline features of the disease. While IGHV mutation status has been already associated with clonal evolution in CLL, 12,34 the relationship between aging and instability of the leukemic clone is an unexpected finding of this study, and might be related to a decline in genomic maintenance mechanisms in older individuals, or a greater propensity of elderly patients to positively select and expand clones harboring high-risk genetic lesions. [35] [36] [37] Regarding the impact on clonal evolution of the baseline genetics of the clone, low risk cases harboring +12 or a normal genotype at diagnosis are characterized by a ~2 fold higher probability of developing poor risk genetic lesions and of switching to the highest risk genetic subgroups compared to very low risk CLL harboring del13q14 only. The relative instability of the Given the growing number of new targeted agents, the management of CLL will conceivably be revised, and early intervention may also become an option. 38, 39 In this changing scenario, 38, 39 there is increasing interest in the use of prognostic markers that may guide management of patients since the early phases of the disease. Our findings may have relevant implications for the design of clinical trials aimed at testing early intervention approaches. In fact, very low-risk cases harboring del13q14 only may not gain any additional benefit from early treatment because of their indolent course, low risk of clonal evolution and nearly normal life expectancy.
Taken together, these data show that the integrated mutational and cytogenetic model can classify CLL patients into more precise subgroups, advance our understanding of the molecular heterogeneity of CLL, and improve current prognostic algorithms. Future challenges are to design rapid and affordable molecular assays and to prospectively define if specific treatments may overcome the poor prognosis conferred by higher risk lesions.
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